| DRUG WATCH |
|
| Year : 2014 | Volume
: 46
| Issue : 5 | Page : 557-559 |
Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma
Anupam Das1, Amrita Sil2, Vivek Mishra1, Nilay Kanti Das1
1 Department of Dermatology, Medical College, Kolkata, West Bengal, India
2 Department of Pharmacology, Institute of Post-Graduate Medical Education and Research, Kolkata, West Bengal, India
Correspondence Address:
Nilay Kanti Das
Department of Dermatology, Medical College, Kolkata, West Bengal
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.140598
Thalidomide developed in 1954 for morning sickness had proven to be a teratogen and hence was withdrawn from market. Resurgence of thalidomide began as an immunomodulator when it was shown to be effective in the management of multiple myeloma and many conditions like erythema nodosum leprosum, graft versus host disease, recurrent aphthous ulcers etc. We report a case of Stevens Johnson syndrome-toxic epidermal necrolysis developing in an elderly male who was prescribed thalidomide after being diagnosed with multiple myeloma.
[FULL TEXT] [PDF]*
|
